Does Rallies show 13F holders for ADMA?

Yes. Rallies tracks hedge fund and 13F ownership data for ADMA, including fund names, share counts, latest tracked quarter, and position changes when available.

Is ADMA research on Rallies investment advice?

No. Rallies provides research, data, and educational context for ADMA. It does not provide personalized investment advice.

ADMA (ADMA Biologics, Inc.) Stock Analysis - Hedge Fund Holdings

ADMA Biologics, Inc. (ADMA) is a publicly traded Healthcare sector company. As of May 21, 2026, ADMA trades at $8.62 with a market cap of $1.94B and a P/E ratio of 12.47. ADMA moved -0.87% today. Year to date, ADMA is -52.52%; over the trailing twelve months it is -58.12%. Its 52-week range spans $7.21 to $25.67. Analyst consensus is buy with an average price target of $23.67. Rallies surfaces ADMA's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

Who owns ADMA stock?

Hedge funds tracked by Rallies that own ADMA include Duquesne Family, Bridgewater Associates, Centerbook Partners, and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ADMA Biologics, Inc..

ADMA Key Metrics

Key financial metrics for ADMA
Metric	Value
Price	$8.62
Market Cap	$1.94B
P/E Ratio	12.47
EPS	$0.69
Dividend Yield	0.00%
52-Week High	$25.67
52-Week Low	$7.21
Volume	3.88M
Avg Volume	0
Revenue (TTM)	$509.86M
Net Income	$165.35M
Gross Margin	61.27%

Top Hedge Funds Holding ADMA

Duquesne Family holds 1.55M shares of ADMA, changed +512.85% as of Mar 31, 2026.
Bridgewater Associates holds 472.11K shares of ADMA, changed +153.18% as of Mar 31, 2026.
Centerbook Partners holds 89.47K shares of ADMA, changed +1.99% as of Mar 31, 2026.
Polen Capital holds 30.41K shares of ADMA, changed +0.00% as of Jun 30, 2025.

Latest ADMA News

ADMA Biologics Flat Q1 Revenue, ASCENIV Sales Jump 28% While BIVIGAM Plunges 54% — May 6, 2026
ADMA Biologics Shares Fall 16% After DSO Hits 113 Days — Mar 30, 2026
ADMA Biologics Refutes Short-Seller Report Over Disclosed Short Position — Mar 25, 2026
ADMA Biologics director buys 7,000 shares at $15.39, posts 28.8% net margin — Mar 9, 2026
Adma Biologics Upgraded to Zacks #1 Strong Buy Following 6.1% Estimate Rise — Mar 3, 2026

Recent ADMA Insider Trades

Grossman Jerrold B bought 12.50K (~$100.13K) on May 12, 2026.
Grossman Jerrold B bought 12.50K (~$100.13K) on May 11, 2026.
Grossman Adam S sold 15.00K (~$227.40K) on Mar 16, 2026.

ADMA Analyst Consensus

3 analysts cover ADMA: 0 strong buy, 2 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is buy. Average price target: $23.67.

Common questions about ADMA

Who owns ADMA stock?: Hedge funds tracked by Rallies that own ADMA include Duquesne Family, Bridgewater Associates, Centerbook Partners, and Polen Capital. The latest tracked quarter is Mar 31, 2026. Rallies shows current holdings, share counts, position changes, and 13F ownership context for ADMA Biologics, Inc..
Does Rallies show 13F holders for ADMA?: Yes. Rallies tracks hedge fund and 13F ownership data for ADMA, including fund names, share counts, latest tracked quarter, and position changes when available.
Is ADMA research on Rallies investment advice?: No. Rallies provides research, data, and educational context for ADMA. It does not provide personalized investment advice.